Table 3 Patterns of disease progression and subsequent outcomes
Characteristics | n = 90 |
|---|---|
PD | 57 (63) |
 RECIST | 51 (89) |
 Clinical | 5 (9) |
 Both | 1 (2) |
Patients with new organ sites at time of RECIST PD | 23 (44) |
New organ sites at time of RECIST PD | |
 Brain | 8 (35) |
 Bones | 1 (4) |
 Liver | 4 (17) |
 Soft tissue | 4 (17) |
 Pleural | 1 (4) |
 Local | 4 (17) |
 Adrenal | 3 (13) |
Management after PD | |
 Subsequent systemic treatment | 28 (49) |
 Hospice | 23 (40) |
 Died | 3 (5) |
Subsequent therapies in PD group after nivolumab discontinued | |
 Cabozantinib | 6 (21) |
 Axitinib | 14 (50) |
 Everolimus | 1 (4) |
 Temsirolimus | 3 (11) |
 Sunitinib | 2 (7) |
 Others* | 2 (7) |